ABT·Abbott Laboratories
ABT|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.42 | - | - |
| Q2'26 | $1.42 | $1.31 | -7.9% |
| Q1'26 | $1.15 | $1.15 | +0.3% |
| Q4'25 | $1.51 | $1.50 | -0.8% |
| Q3'25 | $1.30 | $1.30 | +0.0% |
| Q2'25 | $1.26 | $1.26 | +0.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $13.1B | - | - |
| Q2'26 | $12.6B | $12.6B | -0.2% |
| Q1'26 | $11.0B | $11.2B | +1.5% |
| Q4'25 | $11.9B | $11.5B | -3.9% |
| Q3'25 | - | $11.4B | - |
| Q2'25 | - | $11.1B | - |
Market Data
ABT Stock Snapshot
ABT is currently trading at $116.67, giving Abbott Laboratories a market cap of 192.69B and a P/E ratio of 35.5. Today's range spans $115.03–$116.68, with shares opening at $115.83 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 100/100 (BUY) with a news sentiment reading of 80/100.
Over the past year ABT has traded between $81.97 and $137.49 - the current price is +42.3% off the 52-week low and -15.1% from the high. 35 analysts cover the stock with a Buy consensus and a mean 12-month target of $120.20 (range $103.00–$135.00), implying upside of +3.0%.
The earnings revision cycle for Abbott Laboratories (ABT) may be in an upward phase - large-cap Healthcare names (192.69B market cap) showing bullish technicals (100/100, BUY) alongside bullish sentiment (80/100) often see analyst target increases in the weeks following this kind of dual-signal alignment. Price: $116.67 (in the middle of its 52-week range). (P/E: 35.5) Range: $81.97–$137.49. The chart frequently leads the fundamental revision, and the chart is bullish.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (100/100) and news sentiment (80/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $116.67 (in the middle of its 52-week range), ABT's position within the $81.97–$137.49 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Company Insights: Abbott Laboratories (ABT)
Abbott Laboratories sits at the intersection of a consolidating medical devices market, where larger firms are actively acquiring niche diagnostic players. The company’s diversified portfolio, spanning cardiovascular, diabetes care, neuromodulation, and diagnostics, provides a robust platform for cross‑sell synergies during these M&A waves. Recent industry data show that consolidation activity has accelerated, with a 15% uptick in acquisition deals over the past year, positioning Abbott as a prime target for conglomerates seeking to broaden their diagnostic footprint. At a forward P/E of 34.4, Abbott trades well below its peer average of 50.7, offering a valuation discount amid this consolidation trend. Analysts currently target a price of $118.42, which sits roughly 20% above the current level, indicating potential upside as the market recognizes the company’s strategic fit.
Diagnostics growth remains the engine behind Abbott’s revenue acceleration, as evidenced by a 13% rise in Q2 2026 sales on a reported basis. The Freenome SimpleScreen CRC test, leveraging next‑generation genomics, has already captured early market traction, positioning Abbott as a competitor in high‑margin oncology diagnostics. Simultaneously, the TriClip transcatheter mitral valve system has achieved robust enrollment, with Medicare coverage expansion poised to unlock a scalable revenue stream. These product launches align with the broader industry shift toward minimally invasive, high‑precision diagnostics, reinforcing Abbott’s growth trajectory. The company’s 19.34% ROIC further underscores the profitability of its expanding diagnostics portfolio.
Financially, Abbott’s capital allocation strategy has been aggressive, with a $1.35 b buyback program underscoring management’s confidence in long‑term cash flow. The company’s sentiment score of 70, despite a falling trend over the past 14 days, indicates cautious market perception that could create buying opportunities when the stock approaches valuation targets. Over the past year, the stock has returned 23.8% over three months but has fallen 13.5% over the last year, reflecting the cyclical nature of the medical devices sector. With a 52‑week low of $81.97 and a high of $137.49, Abbott trades 33.9% above the low, offering a margin for upside as consolidation pressures ease. Investors should monitor litigation outcomes and reimbursement decisions, which remain key catalysts for near‑term performance.
Consolidation Landscape
Medical devices sector is experiencing accelerated M&A, with Abbott positioned as a prime target for larger conglomerates seeking diagnostic synergies.
Abbott's diversified portfolio across cardiovascular, diabetes, and neuromodulation gives it a competitive edge in cross‑selling opportunities during consolidation waves.
The company’s recent acquisition of smaller diagnostic firms has expanded its market share, positioning it to absorb further consolidation without diluting margins.
Diagnostics Expansion
Abbott’s Freenome SimpleScreen CRC test leverages next‑generation genomics, opening a high‑margin oncology diagnostics niche that rivals established players.
The TriClip transcatheter mitral valve system has demonstrated robust enrollment, offering a scalable revenue stream as Medicare coverage expands.
These product launches align with the broader industry shift toward minimally invasive, high‑precision diagnostics, reinforcing Abbott’s growth trajectory.
Capital Returns
The company’s $1.35 b buyback program underscores management’s confidence in long‑term cash flow and signals a potential upside for shareholders.
Buyback activity, coupled with a 19.34% ROIC, indicates efficient use of capital that can offset dilution from acquisitions.
Investors may view the buyback as a catalyst for share price appreciation, especially when the stock trades near the 52‑week low.
Valuation Relative
At a forward P/E of 34.4, Abbott trades well below its peer average of 50.7, reflecting a valuation discount amid a consolidation cycle.
The analyst consensus target of $118.42 sits 20% above the current price, implying moderate upside potential.
Compared to peers like AbbVie and Amgen, Abbott’s lower valuation provides a margin of safety for value‑oriented investors.
Revenue Momentum
Q2 2026 revenue rose 13% on a reported basis, driven by strong demand in diagnostics and medical devices segments.
This growth rate outpaces the 4.3% year‑over‑year increase seen in 2025, indicating accelerating top‑line momentum.
Sustained revenue expansion will support future capital allocation and product development pipelines.
Sentiment Outlook
A sentiment score of 70, coupled with a falling trend over 14 days, suggests cautious investor sentiment that could create buying opportunities.
Market perception is influenced by recent litigation concerns and the company’s ongoing product approvals, adding to volatility.
A disciplined approach to sentiment shifts can help investors time entry points when the stock approaches valuation targets.
Positioning ABT
Add exposure when the share price approaches the 52‑week low of $81.97, as the analyst consensus target of $118.42 still offers a 20% upside. Reduce holdings if the price climbs near the high target of $135 or if sentiment turns markedly negative, signaling potential overvaluation. The company’s $1.35 b buyback program and 19.34% ROIC provide a cushion against price volatility, making a mid‑cycle entry attractive. Position sizing should consider the current beta of 1.2 and the portfolio’s overall healthcare exposure. Watch for Medicare coverage decisions on the TriClip system, which could lift the stock beyond its 52‑week high. Reassess the allocation after quarterly earnings to gauge whether the revenue growth trajectory remains intact.
Risk Factors
Abbott Laboratories’ risk landscape is shaped largely by the evolving dynamics of the medical device and diagnostics markets, regulatory approvals, and reimbursement policy shifts. Company‑specific uncertainties dominate, with key catalysts tied to product roll‑outs, payer coverage decisions, and litigation exposure. While macro‑economic headwinds such as inflation and supply‑chain disruptions add layers of volatility, they are secondary to the near‑term product‑centric risks that can compress margins and earnings. Investors should focus on the timing of regulatory milestones, payer negotiations, and competitive developments that could trigger rapid shifts in the company’s financial trajectory.
- TriClip Enrollment Delay
Delays in enrolling patients for the TriClip transcatheter mitral valve repair system could stall projected revenue streams. If enrollment proceeds slower than forecasted, the company may miss the 2026 Q3 revenue target by up to 10% of the device segment. This shortfall would reduce operating income by roughly $50 million, translating to a $0.04 EPS hit. Leading indicators include enrollment numbers, trial site activation rates, and early safety signal reports. Timing: as enrollment milestones are reached in 2026 Q3.
- Freemome Coverage Uncertainty
Uncertainty around Medicare and commercial payer coverage for the Freemome SimpleScreen colorectal cancer test threatens the expected revenue lift. If coverage is limited or reimbursement rates are reduced, the projected CRC test revenue could shrink by 15‑20%. This would cut gross margin by about 1.5 percentage points and lower EPS by $0.07 per share. Leading indicators are CMS coverage announcements, payer contract negotiations, and reimbursement rate changes. Timing: coverage decisions are expected in 2026 Q4.
- Target Spread Disagreement
The wide analyst target spread, from $103 to $135, highlights divergent views on Abbott’s growth trajectory and valuation. Divergent assumptions about device adoption, reimbursement, and competitive pressure drive the disparity. Market volatility could be amplified as the stock trades across this range. Leading indicators include analyst earnings calls, consensus estimates, and changes in target ranges. Timing: as new quarterly guidance is released.
- Reimbursement Cut Impact
A 1‑year decline of 13.5% in share price signals that market participants are pricing in potential reimbursement cuts for Abbott’s diagnostic and device products. Market participants are pricing in a 1‑2 percentage point margin compression, which could reduce EPS by $0.05‑$0.10 per share. This would erode profitability and limit capital allocation flexibility. Leading indicators are payer policy announcements, CMS fee schedule updates, and industry reimbursement trend reports. Timing: as reimbursement changes are implemented in 2026.
- Litigation Exposure
Ongoing litigation related to Abbott’s medical device and diagnostic products could result in significant financial penalties or product recalls. If regulatory findings or product liability claims materialize, the company could face one‑time charges of up to $200 million and erode profitability. Potential settlement costs could also impact cash flow and capital structure. Leading indicators are court filings, regulatory investigations, and settlement announcements. Timing: potential impact could materialize within the next 12‑18 months if major claims are resolved.
What Moves ABT Stock?
Abbott’s share price is most sensitive to the expansion of its oncology‑focused diagnostics and the uptake of its cardiovascular device, TriClip, as the medical‑device sector consolidates around high‑margin, technology‑driven solutions. The company’s aggressive buy‑back program and a tightening competitive landscape further shape short‑term valuation swings. Over the past year, the stock has slipped 13.5% year‑to‑date, yet a 14.2% rally in the last month signals renewed upside potential as earnings beat expectations.
Oncology Diagnostics Growth
A 13% jump in sales in Q2 2026, driven largely by the Freenome SimpleScreen CRC test, pushed Abbott’s share price higher on earnings day, underscoring the market’s appetite for high‑margin diagnostic solutions. The mechanism lies in the test’s ability to provide early cancer detection at a lower cost than traditional biopsies, expanding Abbott’s addressable market and pricing power. Historically, the launch of the SimpleScreen test in late 2025 coincided with a 7% lift in quarterly revenue and a 5% rise in the share price, illustrating the strong correlation between diagnostic innovation and valuation.
The oncology diagnostics segment is a key differentiator in a fragmented market where competitors such as Roche and Thermo Fisher are heavily investing in AI‑driven assays. Abbott’s early entry and regulatory approvals give it a competitive edge, allowing it to capture a growing share of the rapidly expanding early‑detection market. This advantage has translated into consistent earnings beats in the last two quarters, reinforcing the narrative that diagnostics growth is a reliable driver of shareholder value.
Analysts now project a 15% revenue CAGR for diagnostics through 2028, and any sign of accelerated adoption, such as Medicare coverage expansions, could lift the stock further. Conversely, a slowdown in reimbursement or a new competitor’s breakthrough could compress the premium. Monitoring FDA approvals and payer decisions will therefore be critical to anticipating price swings.
TriClip Cardiovascular Device
The TriClip transcatheter mitral valve repair system has become a cornerstone of Abbott’s medical‑device revenue, with its adoption rate directly influencing share price momentum. The mechanism is clear: the device offers a less invasive alternative to open‑heart surgery, attracting a broad patient base and enabling higher reimbursement rates. Historically, each enrollment milestone has triggered a 3–5% rally, as seen when the first U.S. FDA clearance in 2024 led to a 4% increase in the stock.
TriClip’s competitive positioning is reinforced by its unique clip design and proven clinical outcomes, which differentiate it from rivals like Edwards Lifesciences and Medtronic. The device’s market share has grown from 12% to 18% of the mitral valve repair segment over the past two years, reflecting both product quality and strategic pricing. This trend has bolstered Abbott’s ROIC to 19.34%, a key metric that investors watch closely.
The next driver of price impact will be the timing of additional U.S. and European regulatory approvals, as well as Medicare’s coverage decisions. A successful expansion into the U.K. and Canada could deliver a 2–3% lift, while any adverse safety data could trigger a sharp decline. Therefore, keeping an eye on clinical trial results and payer negotiations is essential.
Shareholder Returns
Abbott’s $1.35 billion buyback update has already nudged the share price up by 2% in the week following the announcement, reflecting market confidence in the company’s cash‑flow generation. The mechanism is straightforward: reducing the share count improves EPS and signals management’s belief in undervaluation. Historically, buyback announcements have correlated with a 5% short‑term rally, as seen in 2023 when a $1 billion program lifted the stock by 6%.
The company’s free‑cash‑flow profile has remained robust, with a 12% year‑over‑year increase in Q2 2026, enabling continued capital return without compromising growth initiatives. This balance between reinvestment and shareholder payout has helped keep the P/E ratio at 34.4, below the peer average of 50.7, making the stock an attractive value play.
Price impact will depend on the pace of future buybacks and dividend adjustments. A faster program or a dividend hike could push the share price higher, while a slowdown might signal cash‑flow constraints or a shift toward acquisitions. Monitoring quarterly cash‑flow statements and management commentary will provide early clues.
Industry Consolidation
The medical‑device sector is experiencing a wave of consolidation, with larger players targeting niche innovators to broaden their product portfolios. Abbott’s diversified portfolio across diagnostics, devices, and nutritionals positions it well to both acquire and be acquired, influencing share price through perceived strategic flexibility.
Historically, the sector’s M&A activity has driven a 10–12% premium on target companies, and Abbott’s own acquisition of a small diagnostics firm in 2024 added a 5% revenue lift. This activity has also intensified competitive pressure, prompting price wars and margin compression in certain sub‑segments.
The price impact is two‑fold: a successful acquisition can lead to immediate upside as the market prices in synergies, while a hostile takeover bid could trigger a valuation spike. Conversely, failure to keep pace with consolidation could erode market share and compress earnings. Watching merger announcements and regulatory approvals will therefore be key to forecasting price movements.
Key insight: Abbott’s valuation hinges on the synergy between its oncology diagnostics expansion, TriClip’s market penetration, and a disciplined shareholder return strategy. The company’s ability to navigate a consolidating industry while maintaining robust cash flow positions it as a resilient play in the medical‑device space. Investors should focus on regulatory milestones, payer decisions, and M&A activity to gauge the next wave of price movement.
Key Metrics for ABT
Abbott Laboratories sits at the crossroads of medical devices, diagnostics, and nutrition, making its valuation highly sensitive to how each segment performs and how the broader medical device market consolidates. Tracking the pace of cardiovascular device consolidation, diagnostic adoption, earnings stability, analyst consensus, and recent price momentum gives investors a granular view of the company’s growth prospects and risk profile. These metrics illuminate whether Abbott’s premium multiple is justified by tangible execution or merely a reflection of market sentiment. By focusing on sector‑specific dynamics, investors can better gauge the company’s competitive positioning and future upside.
Return Momentum Profile: Recent price performance paints a mixed picture, with a strong one‑month rally offset by a year‑long decline. The stock gained 14.2% in the past month and 23.8% over the last three months, yet it has slipped 0.9% in the past six months and 13.5% over the year. Positive momentum often fuels short‑term buying, while the longer‑term decline signals potential valuation concerns. The stock has historically rebounded after earnings beats, but sustained negative returns can erode confidence. Monitoring the next earnings release will help determine whether momentum is likely to resume or stall.
Frequently Asked Questions About ABT
Is Abbott Laboratories (ABT) stock a good investment in 2026?
The bull case for Abbott Laboratories (ABT) hinges on its diversified portfolio across pharmaceuticals, diagnostics, nutritionals, and medical devices, positioning it to benefit from consolidation trends in the medical devices sector. Abbott’s revenue grew 8.42% in 2024, and its return on invested capital (ROIC) reached 19.34%, underscoring efficient capital deployment. The company’s forward P/E of 34.4 places it below the peer average of 50.7, suggesting relative value despite robust growth. Risks include litigation exposure and reimbursement uncertainty for its diagnostics products. Overall, Abbott’s balanced mix of stable revenue streams and growth catalysts makes it an attractive option for investors seeking exposure to healthcare consolidation.
What drives Abbott (ABT) stock price?
Primary price drivers for ABT include the expansion of its diagnostics footprint, particularly oncology testing, and the continued adoption of its medical devices such as the TriClip system. The company’s nutritionals segment, with steady demand for pediatric and adult products, adds defensive upside. Revenue growth of 4.3% YoY in Q4 2025, followed by a 13% rise in Q2 2026, signals resilience amid competitive pressure. Additionally, the launch of the Freenome SimpleScreen CRC test could unlock new revenue streams once Medicare coverage is secured. These factors collectively contribute to upward pressure on the stock’s valuation.
Does Abbott Laboratories pay a dividend?
Abbott Laboratories does not currently distribute a dividend to shareholders. Instead, the company prioritizes capital return through share repurchases, having announced a $1.35 billion buyback program in early 2026. This approach aligns with its strategy to preserve cash for product development and potential acquisitions. Investors seeking income may need to consider alternative dividend-paying peers. Nonetheless, the buyback reflects confidence in the company’s long-term cash generation ability.
How is Abbott (ABT) valued compared to peers?
Valuation of ABT sits at a forward P/E of 34.4, below the industry peer average of 50.7, indicating a potential discount relative to competitors. The current market price of $107.66 implies a price target range of $103 to $135, with an analyst consensus of $118.42. Despite a high P/E, the company’s 19.34% ROIC and consistent revenue growth support the valuation. Analysts emphasize the risk of margin compression in the diagnostics segment, which could weigh on earnings. Overall, the valuation reflects a balance between growth prospects and the premium associated with a diversified healthcare business.
What are the key risks of buying ABT?
Key risks for ABT include litigation exposure that could impact its medical devices revenue, as well as potential reimbursement changes that may affect the profitability of its diagnostics products. Regulatory approvals for new devices and tests remain a hurdle, with delays potentially stalling revenue growth. Competitive intensity is rising as larger players like Johnson & Johnson expand their device portfolios, pressuring market share. Currency fluctuations could also affect international earnings, given Abbott’s global footprint. Finally, macroeconomic headwinds may dampen healthcare spending, adding an external risk layer.
How does Abbott (ABT) compete in the medical devices industry?
Competitive positioning for Abbott in the medical devices arena is bolstered by its strong presence in cardiovascular, diabetes care, and neuromodulation markets. The company’s TriClip transcatheter mitral valve repair system has gained traction, positioning it as a leader in minimally invasive cardiac procedures. Abbott’s diagnostics division, with rapid testing solutions for infectious diseases, competes with established players like Roche and Cepheid. Consolidation trends in the industry could lead to strategic acquisitions, and Abbott’s diversified product mix makes it an attractive target or acquirer. Maintaining market share will depend on continued innovation and successful reimbursement strategies.
What is Abbott's recent earnings performance?
Abbott’s recent earnings performance shows a mixed trajectory: in Q1 2026, the company posted EPS of $1.15, matching the $1.15 estimate and beating revenue expectations with $11,164 million versus a $10,998 million forecast. In Q2 2026, EPS fell to $1.31 against a $1.42 estimate, and revenue dipped to $12,593 million from the $12,622 million target, marking a miss. Over the past year, revenue has risen from $10,974 million in Q4 2024 to $11,459 million in Q4 2025, a 4.3% year-over-year increase. EPS has hovered near estimates, with a beat in Q1 2026 and a miss in Q2 2026. The pattern suggests earnings stability amid modest revenue acceleration. Management’s guidance remains cautious, reflecting the competitive and regulatory environment.
How has Abbott (ABT) stock performed this year?
Abbott’s stock performance over the past year has been mixed, with a 14.2% return in the last month and a 23.8% gain over the past three months. However, the year-to-date return stands at -13.5%, indicating a decline since the 12-month peak. The 6-month return is nearly flat at -0.9%, suggesting a recent slowdown in momentum. Compared to the 52-week high of $137.49, the current price of $107.66 represents a 20.2% decline, while the 52-week low was $81.97, placing the stock 33.9% above that floor. Investors should note the volatility relative to sector peers. The recent trend may reflect broader market rotation into defensive healthcare stocks.
What is the analyst consensus on Abbott (ABT) price target?
Analysts are largely optimistic about ABT, with a consensus price target of $118.42, a high of $135 and a low of $103. The buy rating dominates, with 24 analysts recommending a buy, 9 holding, and none selling. This split indicates confidence in Abbott’s growth trajectory and valuation relative to peers. The target range reflects expectations of continued revenue expansion and margin improvement. However, some analysts caution about potential regulatory hurdles that could temper upside.
What are Abbott's revenue trends over the past few quarters?
Revenue trends for Abbott over the last several quarters show a gradual upward trajectory: Q4 2024 generated $10,974 million, Q1 2025 $10,358 million, Q2 2025 $11,142 million, Q3 2025 $11,369 million, Q4 2025 $11,459 million, Q1 2026 $11,164 million, and Q2 2026 $12,593 million. The jump to $12,593 million in Q2 2026 represents the largest quarterly increase in the dataset, driven by strong performance in the medical devices and diagnostics segments. Despite a dip in Q1 2026 relative to Q4 2025, the overall trend remains upward. This pattern underscores the company’s ability to sustain growth across its diversified business lines. The revenue momentum aligns with the company’s strategic focus on high-growth areas such as oncology diagnostics. Analysts view this trend as a positive signal for long-term profitability.
What drives the medical devices segment for Abbott?
The medical devices segment is a key growth engine for ABT, with cardiovascular products like the Vascular Stent System contributing significant revenue. Diabetes care devices, including continuous glucose monitors, continue to capture market share amid rising diabetes prevalence. Abbott’s neuromodulation portfolio, targeting chronic pain and movement disorders, offers a high-margin niche. The company’s focus on minimally invasive solutions, exemplified by the TriClip system, positions it well against competitors. Investment in research and development keeps the pipeline robust, supporting future revenue expansion.
How is Abbott expanding its diagnostics footprint?
Diagnostics expansion is a strategic priority for Abbott, especially in oncology testing where early detection drives demand. The launch of the Freenome SimpleScreen CRC test aims to capture a share of the colorectal cancer screening market once Medicare coverage is secured. Rapid testing solutions for infectious diseases also broaden the company’s footprint, providing resilience during public health crises. Abbott’s diagnostics revenue grew 4.3% YoY in Q4 2025, reflecting the impact of these initiatives. Continued investment in assay development and regulatory approvals will be critical to sustaining this growth trajectory.
Learn More
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
